Erdosteine

Erdosteine

• CAS Number: 84611-23-4
• UNSPSC Description: Erdosteine inhibits lipopolysaccharide (LPS)-induced NF-κB activation[1][2]. Erdosteine has muco-modulatory, anti-bacterial, anti-inflammatory and anti-oxidant effects[3].
• Target Antigen: Bacterial; NF-κB
• Type: Reference compound
• Related Pathways: Anti-infection;NF-κB
• Applications: Metabolism-sugar/lipid metabolism
• Field of Research: Infection; Metabolic Disease; Inflammation/Immunology
• Assay Protocol: https://www.medchemexpress.com/Erdosteine.html
• Purity: 99.83
• Solubility: DMSO : 50 mg/mL (ultrasonic)|H2O : 6.67 mg/mL (ultrasonic)
• Smiles: O=C(O)CSCC(NC(CCS1)C1=O)=O
• Molecular Weight: 249.31
• References & Citations: [1]Park JS, et al. Anti-inflammatory Effect of Erdosteine in Lipopolysaccharide-Stimulated RAW 264.7 Cells. Inflammation. 2016 Aug;39(4):1573-81.|[2]Oktar S, et al. Beneficial effect of erdosteine on methotrexate-induced testicular toxicity in mice. Toxicol Ind Health. 2010 Aug;26(7):433-8.|[3]Recipharm’s proprietary molecule Erdosteine recognised as COPD treatment
• Shipping Conditions: Room Temperature
• Storage Conditions: -20°C, 3 years; 4°C, 2 years (Powder)
• Clinical Information: Launched